Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease

Transgenic mice overexpressing the London mutant of human amyloid precursor protein (APP[V717I]) in neurons develop amyloid plaques in the brain, thus demonstrating the most prominent neuropathological hallmark of Alzheimer's disease. In vivo 3D T2*‐weighted MRI on these mice (24 months of age) revealed hypointense brain inclusions that affected the thalamus almost exclusively. Upon correlating these MRI observations with a panel of different histologic staining techniques, it appeared that only plaques that were positive for both thioflavin‐S and iron were visible on the MR images. Numerous thioflavin‐S‐positive plaques in the cortex that did not display iron staining remained invisible to MRI. The in vivo detection of amyloid plaques in this mouse model, using the intrinsic MRI contrast arising from the iron associated with the plaques, creates an unexpected opportunity for the noninvasive investigation of the longitudinal development of the plaques in the same animal. Thus, this work provides further research opportunities for analyzing younger APP[V717I] mouse models with the knowledge of the final outcome at 24 months of age. Magn Reson Med 53:607–613, 2005. © 2005 Wiley‐Liss, Inc.

[1]  G. Chiro,et al.  T1 and t2 of ferritin at different field strengths: effect on mri , 1992, Magnetic resonance in medicine.

[2]  K. Duff,et al.  Quantitative histological analysis of amyloid deposition in Alzheimer’s double transgenic mouse brain , 2000, Neuroscience.

[3]  S. Bondy,et al.  Promotion of transition metal-induced reactive oxygen species formation by β-amyloid , 1998, Brain Research.

[4]  W. Markesbery,et al.  Oxidative Alterations in Alzheimer's Disease , 1999, Brain pathology.

[5]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[6]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[7]  Koji Abe,et al.  Amyloid cored plaques in Tg2576 transgenic mice are characterized by giant plaques, slightly activated microglia, and the lack of paired helical filament-typed, dystrophic neurites , 2002, Virchows Archiv.

[8]  C. Masters,et al.  Overexpression of Alzheimer's Disease Amyloid-β Opposes the Age-dependent Elevations of Brain Copper and Iron* , 2002, The Journal of Biological Chemistry.

[9]  Susumu Mori,et al.  Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging , 2004, Magnetic resonance in medicine.

[10]  Russell E Jacobs,et al.  Magnetic resonance microscopy of iron in the basal forebrain cholinergic structures of the aged mouse lemur , 1999, Journal of the Neurological Sciences.

[11]  P. Mantyh,et al.  Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of β‐Amyloid Peptide , 1993, Journal of neurochemistry.

[12]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[13]  Z. Qian,et al.  Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders , 1998, Brain Research Reviews.

[14]  Mark A. Smith,et al.  Iron: A Pathological Mediator of Alzheimer Disease? , 2002, Developmental Neuroscience.

[15]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[16]  J. Trojanowski,et al.  In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease , 2000, Neurobiology of Aging.

[17]  I. Tesseur,et al.  Modelling Alzheimer's disease in multiple transgenic mice. , 2001, Biochemical Society symposium.

[18]  D. Feinstein,et al.  A 27‐bp region of the inducible nitric oxide synthase promoter regulates expression in glial cells , 2001, Journal of neurochemistry.

[19]  Thomas Wisniewski,et al.  Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced Magnetic Resonance Imaging , 2002, Neurobiology of Disease.

[20]  G. Zubenko,et al.  Clinically-Silent Mutation in the Putative Iron-Responsive Element in Exon 17 of the β-Amyloid Precursor Protein Gene , 1992, Journal of neuropathology and experimental neurology.

[21]  I. Tesseur,et al.  Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons , 2000, Neurobiology of Aging.

[22]  M. Staufenbiel,et al.  Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy , 2002, Science.

[23]  A J Barkovich,et al.  Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. , 1989, Radiology.

[24]  Marc Dhenain,et al.  Senile plaques do not induce susceptibility effects in T 2*‐weighted MR microscopic images , 2002, NMR in biomedicine.

[25]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[26]  Thomas Wisniewski,et al.  Magnetic Resonance in Medicine 51:794–798 (2004) MRI Assessment of Neuropathology in a Transgenic Mouse Model of Alzheimer’s Disease , 2022 .

[27]  G A Johnson,et al.  Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Veerle Baekelandt,et al.  Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain* , 1999, The Journal of Biological Chemistry.

[29]  J. Richardson,et al.  Brain samples from Alzheimer's patients have elevated levels of loosely bound iron. , 1996, The International journal of neuroscience.

[30]  W. Klein,et al.  Iron Levels Modulate α‐Secretase Cleavage of Amyloid Precursor Protein , 1995, Journal of neurochemistry.

[31]  N. Gelman,et al.  Interregional variation of longitudinal relaxation rates in human brain at 3.0 T: Relation to estimated iron and water contents , 2001, Magnetic resonance in medicine.

[32]  F. Leuven,et al.  Axonal transport, tau protein, and neurodegeneration in Alzheimer’s disease , 2002, NeuroMolecular Medicine.

[33]  B. Gelman,et al.  Iron in CNS Disease , 1995, Journal of neuropathology and experimental neurology.

[34]  M. Staufenbiel,et al.  Cerebral hemorrhage after passive anti-Abeta immunotherapy. , 2002, Science.

[35]  S. Younkin,et al.  Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. , 1993, Science.

[36]  C. Duyckaerts,et al.  Cerebral T2-Weighted Signal Decrease During Aging in the Mouse Lemur Primate Reflects Iron Accumulation , 1998, Neurobiology of Aging.

[37]  P. Hof,et al.  The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis , 1994, Brain Research.

[38]  Thomas Wisniewski,et al.  Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging , 2003, Magnetic resonance in medicine.

[39]  C. Morris,et al.  Non-haem iron histochemistry of the normal and Alzheimer's disease hippocampus. , 1994, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.